Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review

Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions
• Corporate strategy - Analyst’s summarization of the company’s business strategy
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats
• Company history - Progression of key events associated with the company
• Major products and services - A list of major products, services and brands of the company
• Key competitors - A list of key competitors to the company
• Key employees - A list of the key executives of the company
• Executive biographies - A brief summary of the executives’ employment history
• Key operational heads - A list of personnel heading key departments/functions
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history

Highlights

Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd Key Recent Developments

May 19, 2022: Daiichi Sankyo announces changes to representative directors, directors, and audit & supervisory board members
Apr 13, 2022: Ward, Smith & Hill helps secure $41.8M patent infringement victory for biotech company Seagen
Mar 14, 2022: AMRA Medical, Daiichi Sankyo and NCNP joint MRI-based muscle research accepted for poster presentation at 2022 MDA Conference
Jan 12, 2022: Daiichi Sankyo announces reorganization of R&D structure
Nov 26, 2021: Daiichi Sankyo establishes new subsidiaries in Australia, Canada, and Singapore

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs

Note: Some sections may be missing if data is unavailable for the company